세계의 정량 흡입기 시장 : 제품, 추진제, 기술, 적응증, 유통 채널, 지역별 예측(-2032년)

Global Metered Dose Inhalers Market Research Report Information By Product (Press Metered Dose Inhalers, Breath Actuated Metered Dose Inhalers), By Propellant Type (HFA 134A, HFA 227EA, HFA 152A), By Technology (Pulmonary Platform Technologies, Nasal Platform Technologies), By Indication (Asthma, COPD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) Forecast Till 2032

Market Overview

In 2023, the Metered Dose Inhalers Market was estimated to be worth USD 15.8 billion. Over the forecast period (2024-2032), the industry is anticipated to expand from USD 17.1 billion in 2024 to USD 30.0 billion by 2032, with a compound annual growth rate (CAGR) of 6.43%. The global metered-dose inhaler market is experiencing development due to the increasing prevalence of respiratory diseases, the launch of new products by market players, and the increasing awareness and education of the public.

The global MDI market is experiencing significant growth due to the increasing availability of new metered dose inhaler (MDI) products. The technological advancements that these launches bring about, such as improved drug delivery systems and ergonomic designs, are tailored to the preferences of patients for simplicity of use and adherence. Innovative formulations and combinations provide additional therapeutic options for a diverse array of respiratory conditions, thereby enhancing the efficacy of treatment and the quality of patient outcomes.

Market segment insights

The Metered Dose Inhalers Market has been segmented into Press Metered Dose Inhalers and Breath actuated Metered Dose Inhalers based on product.

The Metered Dose Inhalers Market has been segmented into HFA 134a, HFA 227ea, and HFA-152a based on propellant type.

The Metered Dose Inhalers Market has been segmented into pulmonary platform technologies and nasal platform technologies based on technology.

Metered Dose Inhalers Market has been segmented into Asthma, COPD, and other categories based on indication.

Hospital pharmacies, retail pharmacies, and online pharmacies comprise the Metered Dose Inhalers Market, contingent upon their distribution channels.

Regional Perspectives

In 2023, the market share that North America possessed was the most significant. Nevertheless, Asia-Pacific is anticipated to experience the most significant compound annual growth rate (CAGR) during the 2024-2032 forecast period.

The Metered Dose Inhalers market in North America is distinguished by a supportive regulatory environment, technological advancements, and increased healthcare requirements, all of which are driving robust growth. Additionally, the market is driven by the development of state-of-the-art Metered Dose Inhalers, which is made possible by a substantial investment in research and development and a sophisticated healthcare infrastructure.

Europe, which is further divided into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe, follows the Americas region. The Metered Dose Inhalers market in Europe is characterized by a well-established healthcare infrastructure and an increase in healthcare expenditure.

Over the forecast period, the Asia-Pacific region is anticipated to experience robust development, which is driven by a variety of key factors. It is also projected to be the fastest-growing region. The demand for sophisticated inhalers is being driven by the rapid expansion of healthcare infrastructure and the increasing investments in healthcare infrastructure in countries such as China, India, and Japan.

Major Players

AstraZeneca (UK), GSK PLC. (UK), Organon (US), Cipla, Inc. (India), Lupin Pharmaceuticals, Inc. (India), Zydus Group (India), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (US), Aristopharma Ltd. (Bangladesh), and Beximco Pharmaceuticals Limited (Bangladesh) are among the key companies in the Metered Dose Inhalers Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING PRODUCT LAUNCH BY MARKET PLAYERS
  • 4.2.2 GROWING AWARENESS AND EDUCATION
• 4.3 RESTRAINTS
  • 4.3.1 VOLUNTARY PRODUCT RECALL FROM MARKET PLAYERS
  • 4.3.2 STRINGENT REGULATORY POLICIES
• 4.4 OPPORTUNITY
  • 4.4.1 INCREASING INVESTMENT BY PRIVATE AND PUBLIC ORGANIZATION
  • 4.4.2 ONGOING CLINICAL TRIALS ASSOCIATED WITH METERED DOSE INHALER

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL METERED DOSE INHALERS MARKET
• 5.3 KEY TRENDS FOR GLOBAL METERED DOSE INHALERS MARKET

6 GLOBAL METERED DOSE INHALERS MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 PRESS METERED DOSE INHALERS
• 6.3 BREATH ACTUATED METERED DOSE INHALERS

7 GLOBAL METERED DOSE INHALERS MARKET, BY PROPELLANT TYPE

• 7.1 OVERVIEW
• 7.2 HFA 134A
• 7.3 HFA 227EA
• 7.4 HFA-152A

8 GLOBAL METERED DOSE INHALERS MARKET, BY TECHNOLOGY

• 8.1 OVERVIEW
• 8.2 PULMONARY PLATFORM TECHNOLOGIES
• 8.3 NASAL PLATFORM TECHNOLOGIES

9 GLOBAL METERED DOSE INHALERS MARKET, BY INDICATION

• 9.1 OVERVIEW
• 9.2 ASTHMA
• 9.3 COPD
• 9.4 OTHERS

10 GLOBAL METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL

• 10.1 OVERVIEW
• 10.2 HOSPITAL PHARMACIES
• 10.3 RETAIL PHARMACIES
• 10.4 ONLINE PHARMACIES

11 GLOBAL METERED DOSE INHALER MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 US
  • 11.2.2 CANADA
• 11.3 EUROPE
  • 11.3.1 GERMANY
  • 11.3.2 FRANCE
  • 11.3.3 UK
  • 11.3.4 ITALY
  • 11.3.5 SPAIN
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA-PACIFIC
  • 11.4.1 CHINA
  • 11.4.2 INDIA
  • 11.4.3 JAPAN
  • 11.4.4 SOUTH KOREA
  • 11.4.5 AUSTRALIA
  • 11.4.6 REST OF ASIA-PACIFIC
• 11.5 REST OF THE WORLD
  • 11.5.1 MIDDLE EAST & AFRICA
  • 11.5.2 SOUTH AMERICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 MARKET SHARE ANALYSIS,
• 12.3 COMPETITOR DASHBOARD
• 12.4 PUBLIC PLAYERS STOCK SUMMARY
• 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 12.6.1 PARTNERSHIP
  • 12.6.2 PRODUCT LAUNCH/PRODUCT APPROVAL

13 COMPANY PROFILES

• 13.1 ASTRAZENECA
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCTS OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 GSK PLC
  • 13.2.1 COMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCT OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 SWOT ANALYSIS
  • 13.2.6 KEY STRATEGIES
• 13.3 ORGANON GROUP OF COMPANIES
  • 13.3.1 COMPANY OVERVIEW
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCTS OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 KEY STRATEGIES
• 13.4 CIPLA INC.
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 SWOT ANALYSIS
  • 13.4.6 KEY STRATEGIES
• 13.5 LUPIN PHARMACEUTICALS, INC.
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCT OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 SWOT ANALYSIS
  • 13.5.6 KEY STRATEGIES
• 13.6 ZYDUS GROUP
  • 13.6.1 COMPANY OVERVIEW
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 KEY STRATEGIES
• 13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 VIATRIS INC.
  • 13.8.1 COMPANY OVERVIEW
  • 13.8.2 FINANCIAL OVERVIEW
  • 13.8.3 PRODUCTS OFFERED
  • 13.8.4 KEY DEVELOPMENTS
  • 13.8.5 SWOT ANALYSIS
  • 13.8.6 KEY STRATEGIES
• 13.9 ARISTOPHARMA LTD.
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCT OFFERED
  • 13.9.4 KEY DEVELOPMENTS

SOURCE: ANNUAL REPORT AND PRESS RELEASES

• 13.9.5 KEY STRATEGIES
• 13.10 BEXIMCO PHARMACEUTICALS LTD.
  • 13.10.1 COMPANY OVERVIEW
  • 13.10.2 FINANCIAL OVERVIEW
  • 13.10.3 PRODUCTS OFFERED
  • 13.10.4 KEY DEVELOPMENTS
  • 13.10.5 KEY STRATEGIES
• 13.11 DATA CITATIONS